Cargando…

Anisomycin prevents OGD-induced necroptosis by regulating the E3 ligase CHIP

Necroptosis is an essential pathophysiological process in cerebral ischemia-related diseases. Therefore, targeting necroptosis may prevent cell death and provide a much-needed therapy. Ansiomycin is an inhibitor of protein synthesis which can also activate c-Jun N-terminal kinases. The present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Mi-bo, Li, Yu-sheng, Li, Shao-hua, Cheng, Yuan, Zhang, Shuo, Luo, Hai-yang, Mao, Cheng-yuan, Hu, Zheng-wei, Schisler, Jonathan C., Shi, Chang-he, Xu, Yu-ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913227/
https://www.ncbi.nlm.nih.gov/pubmed/29686306
http://dx.doi.org/10.1038/s41598-018-24414-y
Descripción
Sumario:Necroptosis is an essential pathophysiological process in cerebral ischemia-related diseases. Therefore, targeting necroptosis may prevent cell death and provide a much-needed therapy. Ansiomycin is an inhibitor of protein synthesis which can also activate c-Jun N-terminal kinases. The present study demonstrated that anisomycin attenuated necroptosis by upregulating CHIP (carboxyl terminus of Hsc70-interacting protein) leading to the reduced levels of receptor-interacting protein kinase 1 (RIPK1) and receptor-interacting protein kinase 3 (RIPK3) proteins in two in vitro models of cerebral ischemia. Further exploration in this research revealed that losing neither the co-chaperone nor the ubiquitin E3 ligase function of CHIP could abolish its ability to reduce necroptosis. Collectively, this study identifies a novel means of preventing necroptosis in two in vitro models of cerebral ischemia injury through activating the expression of CHIP, and it may provide a potential target for the further study of the disease.